Psoriasis ist eine chronisch-entzündliche Dermatose
mit schubweisem Verlauf. Die bekannteste Komorbidität stellt
die Psoriasisarthritis dar. Im klinischen Alltag fällt
auf, dass Psoriasispatienten häufiger klassische kardiovaskuläre Risikofaktoren
wie Adipositas, Diabetes mellitus, Hyperliproteinämie,
arterielle Hypertonie, Nikotinabusus bis hin zum Metabolischen Syndrom aufweisen
und häufiger an koronarer Herzerkrankung leiden als Nichtpsoriatiker.
Dies konnte durch zahlreiche klinische und epidemiologische Studien
belegt werden. In den letzten Jahren kristallisiert sich zunehmend
die Rolle der Psoriasis als eigenständiger kardiovaskulärer
Risikofaktor heraus, unabhängig von begleitenden klassischen
Risikofaktoren. Dieser Artikel fasst den bisherigen Stand der Kenntnisse
zur Komorbidität zwischen Psoriasis und koronarer Herzerkrankung
zusammen und diskutiert mögliche gemeinsame immunpathologische
Mechanismen.
Abstract
Psoriasis is a chronic inflammtory dermatosis with a relapsing
course. The best known comorbidity is psoriatic arthritis. In daily
clinical practise it is well known, that patients with psoriasis show
more often classic cardiovaskular risk factors such as obesity,
Diabetes mellitus, hyperlipoproteinemia, hypertension, nicotine
abuse often presenting as Metabolic Syndrome and suffer more often
from coronary heart disease than patients without psoriasis. This
could be demonstraded in numerous clinical and epidemiologic studies.
In the last few years there is increasing evidence for psoriasis
beeing an independent cardiovascular risk factor despite of concomitant classic
risk factors. This review summarizes the current state of research
and discusses possible common immunpathogenetic mechanisms.
1
Aicher A, Heeschen C, Mohaupt M. et al .
Nicotine strongly activates dentritic cell-mediated
adaptive immunitiy: potential role for progression of atherosclerotic
lesions.
Circulation.
2003;
107
604-611
2
Alberti K G, Zimmet P Z.
Definition,
diagnosis of diabetes mellitus and its complications, I: diagnosis
and classification of diabetes mellitus provisional report of a
WHO consultation.
Diabet Med.
1998;
15
539-553
3
Alexandroff A B, Pariah Camp R DR, Lang C C, Struthers A D, Armstrong D J.
More than skin deep: atherosclerosis
as a systemic manifesation of psoriasis.
Br J Dermatol.
2009;
161
1-7
6
Choi K H, Hernan M A, Seeger J D. et al .
Methotrexate and mortality
in patients with rheumatoid arthritis: a prospective study.
Lancet.
2002;
359
1173-1177
9
Dixon W G, Watson K D, Lunt M. et al .
Reduction oin the incidence of myokardial
infarction in patients with rheumatoid arthritis who respond to
anti-tumor necrosis factor alpha therapy: results from the British
Society for Rheumatology Biologics Register.
Arthritis
Rheum.
2007;
56
2905-2912
10
Executive Summary of The Third
Report of The National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation and Treatment of High Blood Cholesterol
in Adults (Adult Panel III).
JAMA.
1998;
285
2486-2497
13
Gelfand J M, Weinstein R, Porter S B. et al .
Prevalence and treatment of psoriasis in
the United Kingdom: a population based study.
Arch Dermatol.
2005;
141
11537-11541
15
Gelfand J M, Troxel A B, Lewis J D. et al .
The risk of mortality in
patients with psoriasis: results from a population-based study.
Arch Dermatol.
2007;
143
1493-1499
16
Gisondi P, Tessari G, Conti A, Piaserico S, Peserico A, Gianetti A, Girolomoni G.
Prevalence of metabolic syndrome in patients with psoriasis:
a hospital-besed case-control study.
Br J Dermatol.
2007;
157
68-73
19
Herron M D, Hinckley M, Hofman M S. et al .
Impact of obesity and smoking om psoriasis
presentation and management.
Arch Dermatol.
2005;
141
1527-1534
20
Jacobsson L T, Turesson C, Gülfe A. et al .
Treatment with tunor necrosis factor blockers
is associated with a lower incidence of first cardiovascular events im
patients with rheumatoid arthritis.
J Rheumatol.
2005;
32
1213-1218
22
Kremers H M, Crowson C S, Nicola P J, Ballmann K V. et
al .
Increased unrecognized coronary heart disease and
sudden deaths in rheumatoid arthritis: a population-based cohort
study.
Arthritis Rheum.
2005;
52
402-411
25
Lakka H M, Laaksonen D E, Lakka T A. et al .
The metabolic syndrome and
cardiovascular disease mortality in middle-aged man.
JAMA.
2002;
288
2709-2716
26
Lindegard B.
Diseases associated withpsoriasis in a generl population of 159.200
middle-aged, urban, native Swedes.
Dermatologica.
1986;
172
298-304
27
Ludwig R J, Herzog C, Rostock A, Ochsendorf F R, Zollner T M, Thaci D, Vogl T J, Boehncke W H.
Psoriasis: a possible risk factor for development of coronary artery
calcification.
Br J Dermatol.
2006;
156
271-276
28
Mallbirs L, Akre O, Granath F. et al .
Increased risk for cardiovaskular mortality
in psoriasis inpatients but not in outpatients.
Eur J
Epidemiol.
2004;
19
225-230
29
Mallbris L, Granath F, Hamsten A, Stahle M.
Psoriasis is associated
with lipid abnormalities at the onset of skin disease.
J
Am Acad Dermatol.
2006;
54
614-621
30
Mann D L, McMurray J JV, Packer M, Swedberg K. et al .
Targeted
anticytokine therapy in patients with chronic heart failure: Results
of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
Circulation.
2004;
109
1594-1602
31
McCarey D W, McInnes I B, Mashok R. et al .
Trial of Atorvastatin in Rheumatoid Arthritis
(TARA): double-blind, randomised Placebo-controlled trial.
Lancet.
2004;
363
2015-2021
34
Mehta N N, Azfar R S, Shin D B, Neimann A L, Troxel A B, Gelfand J M.
Patients with severe psoriasis are at increased risk of cardiovascular
mortality: cohort study using the General Practice Research Database.
Eur Heart J.
2010;
31
1000-1006
36
Naldi L, Chatenoud L, Linder D. et al .
Cigarette smoking, body mass index and
stressfull life events as risk factors for psoriasis: results from
an Italian case control study.
J Invest Dermatol.
2005;
125
61-67
37
Neimann A L, Shin D B, Xingmei W, Margolis D J, Troxel A B, Gelfland J M.
Prevalence
of cardiovascular risk factors in patients with psoriasis.
J
Am Acad Dermatol.
2006;
55
829-835
39
Prodanovich S, Ma F, Taylor J R. et al .
Methotrexate reduces incidence of vascular
diseases in veterans with psoriasis or rheumatoid arthritis.
J
Am Acad Dermatol.
2005;
52
262-267
40
Ridker P M.
Testing the inflammatory hypothesis of atherothrombosis: scientific
rationle for the cardiovascular inflammation reduction trial (CIRT).
J Throm Haemost.
2009;
7
(Suppl. 1)
332-339
41
Ridker P M, Danielson E, Fonesca F HA. et al .
Reduction in C-reactive protein and LDL
cholesterol and cardiovacular event rates after initiation of rosuvastatin:
a prospective study oft he JUPITER trial.
Lancet.
2009;
373
1175-1182
42
Rocha-Pereira P, Santos-Silva A, Rebelo I. et al .
Dislipidemia and oxidative stress in mild
and severe psoriasis as a risk for cardiovascular disease.
Clin Chim
Acta.
2001;
303
33-39
44
Setty A R, Curhan G, Choi H K.
Obesity, waist circumference, weight change and the risk of
psoriasis in women: Nurses Health Study II.
Arch Intern Med.
2007;
167
1670-1675
45
Sommer D M, Jenisch S, Suchan M, Christophers E, Weichenthal M.
Increased prevalence of the metabolic syndrome in patients with
moderate to severe psoriasis.
Arch Dermatol Res.
2006;
298
321-328
47
Stern R S, Fitzgerald E, Ellis C N. et al .
The saftey of etretinate as long-term therapy
for psoriasis: results of the etretinate follow-up study.
J
Am Acad Dermatol.
1995;
33
44-52
48
Taler S j, Textor C S, Canzanello V J, Schwartz L.
Cyclosporin-induced
hypertension: incidence, pathogenesis and management.
Drug
Saf.
1999;
20
437-449
49
Wakkee M, Thio H B, Prens E P, Sijbrands E JG, Neumann H AM.
Unfavorable cardiovascular risk
profiles in untreated and treated psoriasis patients.
Atheroslerosis.
2007;
190
1-9
50
Xiao J, Chen L H, TU Y T, Deng X H, Tao J.
Prevalence of myocardial infarction in patients with psoriasis
in central China.
JEADV.
2009;
23
1311-1315
